Related Experiment Video
Updated: May 25, 2026
07:25
In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
Published on: May 4, 2017
Biosimilar rhG-CSFs: how similar are they?
Patricia Gravel1, Aarti Naik, Jean-Yves Le Cotonnec
1Triskel Integrated Services SA, 4 rue des Terreaux-du-Temple, 1201 Geneva, Switzerland.
Targeted Oncology
|February 10, 2012
Summary
Biosimilars, affordable versions of biologic drugs, undergo rigorous European evaluation. This ensures their safety and efficacy are comparable to original biologics, despite abbreviated development.
Area of Science:
- Biopharmaceuticals
- Regulatory Science
- Pharmacoeconomics
Background:
- Biosimilars offer cost-effective alternatives to originator biologics, similar to generic drugs.
- Biological products' complexity necessitates stringent regulatory pathways compared to small molecule generics.
- Recombinant human granulocyte colony stimulating factor (rhG-CSF) biosimilars are a recent advancement in hematopoietic growth factors.
Purpose of the Study:
- To outline the development and authorization process for biosimilars in Europe.
- To analyze physicochemical and clinical data of approved rhG-CSF biosimilars.
- To confirm that rigorous evaluation ensures biosimilar safety and efficacy.
Main Methods:
- Review of European regulatory requirements for biosimilar approval.
- Comparative analysis of physicochemical and clinical data for EU-approved rhG-CSF biosimilars.
- Assessment of scientific data to ensure clinical safety and efficacy.
Main Results:
- European regulatory framework for biosimilars is robust and comprehensive.
- Comparative data demonstrates rhG-CSF biosimilars are highly similar to their reference products.
- Abbreviated development programs are scientifically validated.
Conclusions:
- The European regulatory process ensures biosimilar safety and efficacy.
- Biosimilars, exemplified by rhG-CSF, provide accessible therapeutic options.
- Rigorous scientific scrutiny validates the use of biosimilars.
Related Concept Videos
01:28Drug Products: Biologics, Biosimilars and Interchangeables
Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
01:16Bioequivalence: Overview
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
01:01Regulation of Hematopoietic Stem Cells
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
01:26Pharmaceutical Equivalents
As defined by regulatory standards, pharmaceutical equivalents require generic drug products to have identical dosage forms and chemically identical active pharmaceutical ingredients (APIs). They must adhere to compendial or applicable standards for potency, content uniformity, disintegration times, and dissolution rates. In the case of modified-release dosage forms, variations in drug content are permissible as long as the delivered amount remains consistent with the innovator drug product.
01:22Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...